compound tirzepatide news Compounders lose battle over Eli Lilly weight loss drug and FDA shortage list Tirzepatide: Injection Home Kit –

Barry Conrad It's funny like the amount just with what I do, like the amount of times I have to like stick myself for things

The short answer: there is promising but limited evidence

Enjoy it while it lasts

Sandstrom, Paul A

Research Evidence Comparison# Survodutide Research# Survodutide's clinical evidence is growing but remains primarily Phase 2: Phase 2 obesity trial : Randomized, dose-ranging study demonstrated up to 18.7% body weight loss at 46 weeks with the 4.8 mg dose, with dose-dependent efficacy across all arms Phase 2 MASH trial : Demonstrated significant reductions in liver fat content measured by MRI-PDFF, with histological improvement in MASH activity scores including inflammation and ballooning